No Data
No Data
新銳醫藥:2023年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Xinrui Pharmaceuticals (06108) announced annual results. The net loss attributable to shareholders was about HK$22.2 million, a year-on-year narrowing of about 71.5%
According to the Zhitong Finance App, Xinrui Pharmaceutical (06108) announced results for the year ended December 31, 2023, with revenue of about HK$50.2 million, a year-on-year decrease of 44.1%; net loss attributable to the company's owners was about HK$22.2 million, a year-on-year decrease of about 71.5%; and a loss of 1.33 HK cents per share. The decline in revenue was mainly due to the further strengthening of the hierarchical classification management policies for the adoption of antimicrobials in many regions of mainland China, and the adverse effects continued. As a result, demand for the Group's main product, second-generation cephalosporin products (1.0g), declined this year.
No Data